47 reports

  • Respiratory Drugs Market Characteristics
  • Respiratory Drugs Market Forecast Growth
  • Respiratory Treatment
  • World
  • Market Size
  • AstraZeneca PLC
  • Merck & Co., Inc.
  • RESPIRATORY DRUGS MARKET IN EMEA
  • RESPIRATORY DRUGS MARKET IN APAC
  • Respiratory Treatment
  • AstraZeneca PLC
  • GlaxoSmithKline plc
  • Merck & Co., Inc.
  • Novartis AG

Decline in the global sales of respiratory medicines such as Seretide/ Advair, Flixotide/ Flovent, and Ventolin.

  • Allergy Drug
  • Respiratory Treatment
  • AstraZeneca PLC
  • Merck & Co., Inc.
  • Sanofi S.A.
  • KEY NEWS
  • Respiratory Treatment
  • AstraZeneca PLC
  • Boehringer Ingelheim GmbH
  • F. Hoffmann-La Roche Ltd.
  • Merck & Co., Inc.
  • Key vendor analysis

Develops drugs for the treatment of respiratory indications.

  • Respiratory Treatment
  • World
  • AstraZeneca PLC
  • Boehringer Ingelheim GmbH
  • Novartis AG
  • Strength
  • Vendor landscape
  • Respiratory Treatment
  • AstraZeneca PLC
  • GlaxoSmithKline plc
  • Merck & Co., Inc.
  • Novartis AG
  • RESPIRATORY DRUGS INDUSTRY ASSESSMENTS
  • Respiratory Drugs Companies in China
  • Respiratory Treatment
  • China
  • Demand
  • Market Size
  • Zhongmei Shike Pharmaceutical Co., Ltd
  • Respiratory Drugs Market Overview
  • IV. RESPIRATORY DRUGS PRODUCTION AND DEMAND
  • Respiratory Treatment
  • China
  • Demand
  • Market Size
  • Trade
  • Respiratory Drugs Markets in China
  • V. RESPIRATORY DRUGS MARKET OUTLOOK
  • Respiratory Treatment
  • China
  • Demand
  • Market Size
  • Trade
  • Respiratory Drugs
  • Prescription Drugs Production and Demand (million Yuan)
  • Prescription Drug
  • Respiratory Treatment
  • China
  • Demand
  • Supply
  • BOEHRINGER INGELHEIM

It undertakes the development of drugs for the treatment of respiratory disorders.

  • Respiratory Treatment
  • AstraZeneca PLC
  • Boehringer Ingelheim GmbH
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline plc
  • Respiratory Drugs Import Volume and Market Share
  • Anti-infective Drugs Import Volume and Market Share
  • Respiratory Treatment
  • China
  • Demand
  • Roche Group
  • Xincat Pharmaceutical Co., Ltd.
  • Prescription Drugs Industry Capacity (million Yuan)
  • Chapter III

Chapter IV PRESCRIPTION DRUGS PRODUCTION AND DEMAND Table ##: Pain and Fever Relief Drugs Production and Demand (Million Yuan) Respiratory Drugs RESPIRATORY DISEASE IS THE TERM FOR DISEASES OF THE RESPIRATORY SYSTEM.

  • Respiratory Treatment
  • China
  • Demand
  • Supply
  • Zhejiang Expressway Co., Ltd.
  • Respiratory Drugs Import Volume and Market Share
  • Anti-infective Drugs Import Volume and Market Share
  • Respiratory Treatment
  • China
  • Demand
  • Market Size
  • Roche Group
  • RESPIRATORY DISORDERS THERAPEUTICS MARKET, GLOBAL, MERCK & CO. ANNUAL REVENUE

S BESTSELLING RESPIRATORY TREATMENT THROUGHOUT THE FORECAST PERIOD.

  • Respiratory Treatment
  • World
  • Market Size
  • Astellas Pharma Inc.
  • AstraZeneca PLC

There are five main molecular targets within the respiratory therapy.

  • Respiratory Disease
  • Respiratory Treatment
  • Therapy
  • World
  • Market Size
  • CHIESI'S COPD PORTFOLIO ASSESSMENT, 2017
  • 10.3.3 CHIESI

IN 2007, ASTRAZENECA ACQUIRED MEDIMMUNE AND ITS MANY RESPIRATORY DRUGS THAT WERE IN DEVELOPMENT AT THAT TIME.

  • Respiratory Treatment
  • Demand
  • AstraZeneca PLC
  • Boehringer Ingelheim GmbH
  • Sunovion Pharmaceuticals Inc.

Beyond these two drugs, the company' s other respiratory complications therapies will contribute very little revenue.

  • Respiratory Treatment
  • World
  • Market Size
  • Actelion Ltd
  • Pfizer Inc.
  • Global respiratory drugs market
  • Global respiratory drugs market 2015-2020 ($ billions)
  • Respiratory Treatment
  • China
  • AstraZeneca PLC
  • Merck & Co., Inc.
  • Novartis AG
  • GLOBAL RESPIRATORY SYNCYTIAL VIRUS DRUGS MARKET

SEGMENTATION OF GLOBAL HUMAN RESPIRATORY SYNCYTIAL VIRUS DRUGS MARKET BY TYPE OF DRUG 2015 Off-label drugs ##% THIS SEGMENT CONSISTS OF A SINGLE APPROVED DRUG, SYNAGIS, WHICH IS A LARGE MOLECULE DRUG.

  • Respiratory Treatment
  • World
  • AbbVie Inc.
  • AstraZeneca PLC
  • Teva Pharmaceutical Industries Ltd.
  • 10. Market Segmentation by Therapeutic Application
  • 03.2 Product Offerings
  • Anti-Infective
  • Respiratory Treatment
  • Japan
  • Meiji Seika Pharma Co., Ltd.
  • Nipro Corporation

Respiratory Merck (2013).

  • Asthma
  • Respiratory Treatment
  • Therapy
  • World
  • AstraZeneca PLC
  • TEVA'S AR PORTFOLIO ASSESSMENT, 2014
  • 4.3.5 TEVA

GSK currently has the world' s most successful respiratory drug franchise.

  • Respiratory Treatment
  • GlaxoSmithKline plc
  • GlobalData's company
  • Merck & Co., Inc.
  • Sanofi S.A.
  • 23.1 COMPETITIVE SCENARIO

They block ILs, which cause inflammation in the respiratory tract.

  • Respiratory Treatment
  • AstraZeneca PLC
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline plc
  • Merck & Co., Inc.
  • Clinical Trial Profile Snapshots

DRUG/ MOLECULE REFERS TO PRIMARY INTERVENTION ONLY. ##.

  • Hospital
  • Respiratory Treatment
  • AstraZeneca PLC
  • Boehringer Ingelheim GmbH
  • GlaxoSmithKline plc
  • TEVA'S AR PORTFOLIO ASSESSMENT, 2014

GSK CURRENTLY HAS THE WORLD' S MOST SUCCESSFUL RESPIRATORY DRUG FRANCHISE.

  • Respiratory Treatment
  • Forecast
  • Market Size
  • Merck & Co., Inc.
  • Sanofi S.A.
  • Clinical Trial Profile Snapshots

Drug/ Molecule refers to Primary Intervention only. ##.

  • Respiratory Treatment
  • AstraZeneca PLC
  • Boehringer Ingelheim GmbH
  • GlaxoSmithKline plc
  • Novartis AG
  • FIVE MAJOR EU MARKETS PAYER INSIGHTS
  • IL-5 INHIBITORS

" [RESPIRATORY INHALER SPEND] IS EXCESSIVE.

  • Asthma
  • Respiratory Treatment
  • Europe
  • ESI Group
  • GlaxoSmithKline plc

Coughing, a reflex mechanism, helps eliminate secretions from the respiratory tract.

  • Respiratory Treatment
  • United States
  • GlaxoSmithKline plc
  • Merck & Co., Inc.
  • Pfizer Inc.
  • INVION COMPLETES RIGHTS OFFERING OF SHARES FOR USD0.8 MILLION

Invion' s products are especially suitable for combination with existing respiratory drugs because of their unique antiinflammatory profiles.

  • Pharmaceutical
  • Respiratory Treatment
  • Australia
  • M&A
  • Invion Limited